June 17, 2024 03:31 PM EDT
Pharma
FDA+

FDA ap­proves en­dome­tri­al can­cer in­di­ca­tions for Keytru­da, Imfinzi

Nicole DeFeudis

Editor

The FDA has grant­ed two new en­dome­tri­al can­cer in­di­ca­tions to ri­val im­munother­a­pies: Mer­ck’s Keytru­da and As­traZeneca’s Imfinzi.

On Mon­day, reg­u­la­tors

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times